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Two recent publications report the design of immunogens based on the conserved stalk domain of the
influenza virus hemagglutinin. These new ‘‘headless’’ hemagglutinin constructs recapitulate the epitopes
recognized by broadly neutralizing antibodies and induce broadly protective/heterosubtypic immunity in
animal models, bringing us a step closer to ‘‘universal’’ influenza virus vaccines.Influenza viruses escape human herd
immunity by continuously changing their
surface antigens, a process called anti-
genic drift. Due to this antigenic drift
influenza virus vaccines have to be
reformulated and re-administered on an
annual basis. The discovery of broadly
neutralizing antibodies against the rela-
tively conserved stalk domain of the viral
hemagglutinin (HA) in recent years has
spurred the development of ‘‘universal’’
influenza virus vaccines. Unfortunately,
however, it is difficult to induce anti-
bodies against this domain with standard
vaccines due to the immunodominance
of the membrane distal globular head
domain of the HA, which is the region
most affected by antigenic drift.
The immunosubdominance of the
stalk domain has been an obstacle for
the development of broadly protective
stalk-based vaccines. The seemingly
obvious solution to this problem is the
removal of the immunodominant globular
head domain resulting in a stalk-only or
headless HA. The first approach toward
a headless HA was reported by Graves
et al. (1983) (Table 1). By exposing influ-
enza virions to acidic and reducing
conditions it was possible to remove
the HA1 subunit (which includes the
whole head domain) and generate virions
with an exposed HA2 subunit (which
includes most of the stalk domain). At
that point, it was not clear that broadly
neutralizing anti-stalk antibodies bind
to conformational epitopes that require
correctly folded pre-fusion stalk domains.
In fact, the chemical treatment of the
virions had destroyed those fragile
epitopes. Furthermore, the N- and C-ter-
minal parts of the HA1—which were
completely removed by this approach—
are part of the stalk domain, as well.
Studies by (Sagawa et al. (1996) and Steelet al. (2010) genetically removed the
globular head domain. These vaccine
constructs proved to have protective
potential in the mouse model, but the
removal of the globular head domain
most likely led to the misfolding of the
resultant headless HA immunogens and
concomitant destruction of important
neutralizing epitopes. Bommakanti et al.
(2012) reported an alternative version of
a headless HA expressed in E. coli. While
this construct was protective against
mortality from a heterologous virus chal-
lenge, its conformation was likely far
from optimal. A follow up study by (Malla-
josyula et al. (2014) reported enhanced
structural integrity and improved efficacy
in the mouse model. Another recent
study by Lu et al. (2014) involved a multi-
step rational design approach and led
to a construct that displayed correctly
folded conformational epitopes of broadly
neutralizing antibodies. However, no re-
ports of the in vivo efficacy of this immu-
nogen were published. Finally, Wohlbold
et al. (2015) showed that a soluble recom-
binant headless HA produced in insect
cells provided protection against lethal
H1N1, H5N1, and H6N1 challenges
despite the fact that the immunogen was
not folded correctly.
In two very elegant recent studies Im-
pagliazzo et al. (2015) and Yassine et al
(2015) independently reported methods
for making stable, correctly folded head-
less HA molecules (Figure 1; Table 1).
While both studies take different paths
to success, they share common design
elements. Previous headless HA ap-
proaches focused on stabilizing the
molecule by adding a ‘‘clamp’’ (usually a
trimerization domain) at the membrane
proximal end of the molecule. This
approach initially appeared sensible, as
this portion of the molecule is normallyCell Host & Microbe 18stabilized by the transmembrane domain
in virion-associated HA. However, this
design does not improve the stability of
the membrane-distal part of the headless
HA, which exposes a relatively hydropho-
bic surface that is usually hidden below
the head domain. The introduction of a
stabilizing element in this region led to
success for both new approaches.
Instead of introducing a trimerization
domain at the membrane distal end of
the HA, Impagliazzo et al. chose to
replace the upper part of the central long
alpha helix of HA2 with a leucine zipper
trimerization domain (which also forms
a helix). Similarly, Yassine et al. fused
an HIV gp41 trimerization domain to the
upper part of the long alpha helix. While
Yassine et al. removed this design
element from the final version of their
immunogen, the introduced leucine
zipper remains as an important stabilizer
in the Impagliazzo headless HA. In addi-
tion, both groups used the stalk domains
from pre-pandemic H1N1 strains as the
framework for the headless HA design.
This framework might have contributed
to success since the stalk domain from
2009 pandemic H1N1 viruses is less
stable. Structural characterization and
binding analysis with broadly neutralizing
anti-stalk monoclonal antibodies (mAbs)
provide evidence of the structural integrity
of both constructs. Importantly, both
constructs induce stalk-reactive anti-
bodies in animals and protect against
heterosubtypic challenge with highly
pathogenic H5N1 viruses. Interestingly,
this protection was achieved in the
absence of robust neutralizing antibody
titers. However, stalk-reactive antibodies
are known to protect through several
mechanisms including inhibition of entry,
inhibition of viral egress, inhibition of
HA maturation and via effector functions, October 14, 2015 ª2015 Elsevier Inc. 395
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Figure 1. Novel Headless HA Constructs and Overview of Headless HA Studies Based on
Group 1 Hemagglutinins
(A) Structure of full length A/California/04/09 H1 HA based on PDB# 4M4Y. The membrane proximal stalk
domain is indicated in blue, the membrane distal globular head domain is shown in red. Cysteines 52 and
277 (H3 numbering) which form the demarcation line between the head and the stalk domain are shown in
yellow.
(B) Structure of one of the intermediated stalk constructs (generation 4) from Yassine et al. The structure is
based on PDB# 5C0S.
(C) The headless HA construct from (B) bound by Fab fragments of broadly neutralizing anti-stalk mAb
CR6261 (green). Of note, the gp41 trimerization domain present in PDB 5C0S is not shown in (B) and (C) to
simplify the concept.
Table 1. Summary Table of Group 1 Headless HA Studies
Study HA Basis Platform/Construct
Homologous
protection
Heterosubtypic
protection Stalk mAb binding
Graves et al. (1983) H1 (A/PR/8/34)
and others
Virus particles ND1 ND ND, unlikely
Sagawa et al.(1996) H2 (A/Okuda/57) Transfected cells ND H1N1: 70%2 mAb C179 binding
confirmed by
immunostaining
Steel et al. (2010) H1 (A/PR/8/34)
and others
Virus-like particles Yes2 ND No, as shown by
Impagliazzo et al.
Bommakanti
et al. (2012)
H1 (A/PR/8/34),
(A/NC/20/99),
(A/California/07/09)
Bacterial expression
of soluble protein
Yes2 ND mAb CR6261 binding
by surface plasmon
resonance (SPR)
Lu et al. (2014) H1 (A/California/05/09) Cell free synthesis
of soluble protein
ND ND mAb CR6261, FI6 and C179
binding in capture ELISA
Mallajosyula
et al. (2014)
H1 (A/PR/8/34) Bacterial expressed
soluble protein
Yes2 H3N2: 30%2
(control: 10%)
mAb CR6261, FI6 and F10
binding by SPR
Wohlbold et al. (2015) H1 (A/PR/8/34) Insect cell expressed
soluble protein
Yes2 H5N1: 60%2
H6N1: 100%2
No binding with panel
of stalk mAbs in direct
coating ELISA
Impagliazzo
et al. (2015)
H1 (A/Brisbane/59/07) Mammalian cell
expressed soluble
protein
Yes2 Non-human
primates:
reduced fever
H5N1: 100%2 Binding of CR9114 and
CR6261(ELISA, structural
methods, SPR)
Yassine et al. (2015) H1 (A/NC/20/99) Mammalian expressed
ferritin nanoparticles
ND H5N1: 100%2
Ferrets
H5N1: 67%
Binding of a panel
of anti-stalk mAbs
(ELISA, structural
methods, SPR)
1Not determined.
2A as tested in the mouse model.
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In Translationlike antibody dependent cell-mediated
immunity (ADCC) and complement
dependent cytotoxicity. High levels of
in vitro neutralizing antibodies might
therefore not be required for robust
stalk-based protection.
The construction of stable headless HA
constructs is an important step toward
the development of a universal influenza
virus vaccine. However, there are several
caveats associated with this approach.
Both constructs include heterologous ele-
ments that raise concerns about autoim-
munity. Leucine zipper motifs, such as
those used in the Impagliazzo construct
are common in nature and proteins with
very similar sequences exist in humans.
The bacterial ferritin scaffold used by
Yassine and colleagues is highly immuno-
genic. The primary sequences of bacterial
and mammalian ferritins show little
sequence identity but a high degree of
structural similarity exists between them.
While the authors show in earlier studies
that these ferritin scaffolds do not induce
autoimmunity in inbred mice (Kanekiyo
et al., 2013), humans who are predis-396 Cell Host & Microbe 18, October 14, 201posed to autoimmune disease may react
differently. In addition, the strong immu-
nogenicity (immunodominance) of the5 ª2015 Elsevier Inc.scaffold might reduce the immune
response against the subdominant HA
stalk domain. Furthermore, headless
Cell Host & Microbe
In TranslationHA constructs expose regions of the HA
stalk, which are usually not accessible to
the humoral immune system. It is there-
fore possible that a large proportion of
antibodies induced by these headless
HA constructs are unable to neutralize—
or even bind—to native HA spikes on
virions. Finally, both headless HA con-
structs are based on the stalk of an H1
HA, which belongs to group 1 HAs. In
order to protect against currently circu-
lating drift variants, a group 2 stalk-based
headless HA as well as an influenza
B stalk-based headless HA would be
needed in a universal influenza virus vac-
cine formulation. It is unclear if designs
similar to those used by Impagliazzo
et al. (2015) and by Yassine et al. (2015)
would also lead to stable group 2 and B
headless HAs or if novel unique construct
designs are needed. Although many open
questions remain, the successful design
of such elegant headless HA constructs
(Impagliazzo et al., 2015; Yassine et al.,2015) is an important advancement in
the direction of a truly universal influenza
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